RU
Address
220006, Minsk, Leningradskaya Str. 6, office 2
Tel.: +375 17 363-88-92
E-mail: medjournal@bsmu.by

Бактериемия у госпитализированных пациентов с COVID-19: частота развития и факторы риска

Е. А. Сильванович, Д. В. Литвинчук УО «Белорусский государственный медицинский университет»
DOI:  https://doi.org/10.51922/1818-426X.2026.4.110
2026 №4 | Оригинальные научные публикации
Аннотация
Список литературы
Скачать полнотекстовую статью
Цель исследования: оценить частоту развития и факторы риска бактериемии у госпитализированных пациентов с COVID-19 в различные периоды пандемии.
Методы. В исследование включены 11203 пациента, госпитализированных с диагнозом COVID-19 в УЗ «Городская клиническая инфекционная больница» г. Минска в период с марта 2020 по июнь 2023 гг. Оценка частоты встречаемости бактериемии и факторов риска, ассоциированных с ее развитием в условиях конкурирующих рисков, выполнялась с использованием моделей причинно-специфической регрессии Кокса. Статистический анализ выполнялся в R 4.3.4.
Ключевые слова:
COVID-19, бактериемия, бактериальные осложнения, факторы риска, SARS-CoV-2.
Bacteremia in hospitalized patient with COVID-19: incidence and risk factors

Aim. The aim of the study is to assess the incidence and risk factors of bacteremia in hospitalized patients with COVID-19 during different periods of the pandemic.
Methods. The study included 11203 patients diagnosed with COVID-19 who were hospitalize in Minsk City Clinical Infectious diseases Hospital, from 1 June 2021 to 30 June 2023. The incidence of bacteremia and risk factors associated with its development in conditions of competing risks were assessed using Cox cause-specific regression models. Statistical analysis was performed in R 4.3.4.

Keywords
COVID-19, bacteremia, bacterial complications, risk factors, SARS-CoV-2.
    • WHO COVID-19 dashboard [Electronic resource]. – Access of mode: https://data.who.int/dashboards/covid19/deaths?n=c. – Access of date: 04.05.2026. 
    • Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications / A. T. Levin [et al.] // Eur. J. Epidemiol. – 2020. – Vol. 35, № 12. – P. 1123–1138. 
    • Bloodstream infections in critically ill patients: an expert statement / J.-F. Timsit [et al.] // Intensive Care Med. – 2020. – Vol. 46, № 2. – P. 266–284. 
    • Приказ № 690 О вопросах лечения пациентов с инфекцией COVID-19: Приказ Министерства здравоохранения Республики Беларусь: Минск. № 690 от 01.07.2020 г. 56 с.; Prikaz №690 O voprosah lecheniya pacientov s infekciej COVID-19: Prikaz Ministerstva zdravoohraneniya Respubliki Belarus’: Minsk. № 690 ot 01.07.2020 g. 56 s. [Order № 690 on the Treatment of Patients with COVID-19 Infection: Order of the Ministry of Health of the Republic of Belarus: Minsk. № 690 dated July 1, 2020. 56 p.]. [In Russian] 
    • Understanding the mechanisms and drivers of antimicrobial resistance / A. H. Holmes [et al.] // The Lancet. – 2016. – Vol. 387, № 10014. – P. 176–187.
    • Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration / R. Chen [et al.] // Front. Immunol. – 2021. – Vol. 12 – С. 589095.
    • Delano, M. J. The immune system’s role in sepsis progression, resolution, and long-term outcome / M. J. Delano, P. A. Ward // Immunol. Rev. – 2016. – Vol. 274, № 1. – P. 330–353.
    • Impact of Dexamethasone on the Pathogen Profile of Critically Ill COVID-19 Patients / C. Kodde [et al.] // Viruses. – 2023. – Vol. 15, № 5. – P. 1076. 
    • Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study / T. Mueller [et al.] // BMJ Open. – 2022. – Vol. 12, № 12. – P. e064320. 
    • Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and metaanalysis / A. Chapman [et al.] // Int. J. Infect. Dis. – 2025. – Vol. 158. – P. 107958. 
    • Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study / C. Garcia-Vidal [et al.] // Clin. Microbiol. Infect. – 2021. – Vol. 27, № 1. – P. 83–88. 
    • Austin, P. C. Introduction to the Analysis of Survival Data in the Presence of Competing Risks / P. C. Austin, D. S. Lee, J. P. Fine // Circulation. – 2016. – Vol. 133, № 6. – P. 601-609. 
    • Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York City / J. Sepulveda [et al.] // J. Clin. Microbiol. – 2020. – Vol. 58, № 8. – P. e00875-20. 
    • Risk factors associated with bacteremia in COVID-19 patients admitted to intensive care unit: a retrospective multicenter cohort study / C. Bonazzetti [et al.] // Infection. – 2023. – Vol. 51, № 1. – P. 129–136. 
    • Wang, J. Risk factors for bloodstream infection in COVID-19 patients in intensive care units: a systematic review and metaanalysis / J. Wang, T. Jiang // BMC Infect. Dis. – 2025. – Vol. 25, № 1. – P. 13. 
    • Global Burden of Bloodstream Infections in COVID-19: Prevalence, Antimicrobial Resistance, and Mortality Risk / D.-M. Mateescu [et al.] // Viruses. – 2025. – Vol. 17, № 10. – P. 1353. 
    • Antibiotic Treatment in Patients Hospitalized for Nonsevere COVID-19 / M. S. Pulia [et al.] // JAMA Netw. Open. – 2025. – Vol. 8, № 5. – P. e2511499.